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Dear Editor, 
 
Cancer remains one of the leading causes of global morbidity and mortality, with approx-
imately 14 million new cases and 8.2 million cancer related deaths in 2012 (Stewart and Wild, 
2014). Treatment protocols include radiation, surgery, chemotherapy, hormone therapy, im-
munotherapy and targeted therapy (American Cancer Society, 2015). While chemotherapy is 
one of the key strategies against cancer, the available drugs are frequently fraught with toxici-
ty and increased frequency of tumor relapse (Gaziano et al., 2016). This calls for an urgent 
need for more effective anti-tumor agents especially from phytochemicals which are known to 
be of lower toxicity and cost (Reddy et al., 2003). A wide variety of phytochemicals, particu-
larly alkaloids, have been investigated in recent times in the quest for more effective and safer 
antitumor agents (Lu et al., 2012; Kharwar et al., 2011). Interestingly, several important anti-
tumor alkaloidal drugs have been isolated from medicinal plants including the vinca alkaloids, 
vinblastine and vincristine, isolated from the Madagascar periwinkle, Catharanthus roseus 
(Noble et al., 1958; Johnson et al., 1959; Svoboda, 1961) as well as paclitaxel, isolated from 
Taxus brevifolia (Wani et al., 1971). One effective strategy employed by scientists in this re-
gard is the investigation of known drugs for novel biological effects, the so called ‘drug repo-
sitioning’. One of such known drugs that have been shown to possess anti-tumor activity is 
the alkaloidal amoebicidal drug, emetine (EMT).  
EMT, chemically designated as 2S,3R,11bS)-2-{[(1R)-6,7-dimethoxy-1,2,3,4-tetrahydro-
isoquinolin-1-yl]methyl}-3-ethyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido [2,1-
a]isoquinoline (Figure 1), is an isoquinoline alkaloid which occurs in the families of Alan-
giaceae, Icacinaceae, and Rubiaceae. The major source of EMT and its analogs is Psychotria 
ipecacuanha Stokes (Rubiaceae) which is also known as Cephaelis ipecacuanha A. Rich (ip-
ecac) where it is the principal alkaloid (Wiegrebe et al., 1984). It is clinically used (as a dihy-
drochloride) in the treatment of amoebiasis, a protozoan infection (Vedder, 1912) and it has 
emetic properties. It is reportedly a protein synthesis inhibitor in eukaryotes (Grollman, 
1968). The biosynthesis of EMT and cephaeline (another alkaloid found in ipecac) comes 
from two main biosynthesis pathways, the biosynthesis of dopamine from L-tyrosine and that 
of secologanin from geranyl diphosphate (Cheong et al., 2011; Nomura et al., 2010). 
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Figure 1: Chemical structure of EMT 
 
 
The anti-cancer effect of EMT was first reported on malignant human tumors in 1918 by 
Lewisohn (1918) but since he was unable to reproduce this effect in laboratory animals, he 
concluded that the drug had no anti-tumor properties and that the tumor regression must have 
been spontaneous. However, in the following year, Van Hoosen (1919) further reported the 
remission of various malignancies in a number of patients by EMT. This is followed in later 
years by reports of effectiveness of EMT in rat Yoshida sarcoma (Isaka, 1950), intra-
abdominal and retroperitoneal nonspecific granulomas (Grollman, 1965) and in murine leu-
kemia (Jondorf et al., 1970). Besides, the potency of an analogue of EMT, dehydroemetine, 
was also shown in chronic granulocytic leukemia (Abd-Rabbo, 1966), various malignancies 
(Abd-Rabbo, 1969) as well as in Hodgkin's disease and rectal adenocarcinoma (Wyburn-
Mason, 1966). Based on these reports, phase I and II clinical trials with EMT were done in the 
early 1970s (Panettiere and Coltman, 1971; Street, 1972; Mastrangelo et al., 1973; Siddiqui et 
al., 1973; Moertel et al., 1974; Kane et al., 1975). The drug was, however, discontinued from 
the clinical trials (Von Hoff et al., 1977) due to its very narrow therapeutic index, cardiac tox-
icity and other adverse effects which were also observed in the treatment of amoebic patients 
(Knight, 1980). Since then the drug has been used in in vitro experimental studies requiring 
inhibition of protein biosynthesis (Akinboye et al., 2012). The data from these recent studies 
have further shown EMT as a modulator of different cancer related biological pathways. In 
fact, excellent review by Akinboye and Bakare (2011) has shown that EMT exhibits its anti-
tumor effect by apoptosis through such mechanisms as inhibition of protein biosynthesis, 
DNA interaction and regulation of pro-apoptotic factors. In more recent years also, various 
studies have further investigated the role of EMT in cancer growth arrest and its biological 
targets using a variety of human carcinoma cell lines. New derivatives have also been synthe-
sized and reported to be efficacious but less toxic to normal cells. Also the drug has been in-
vestigated in combination with other agents to assess their anti-tumor synergistic effect which 
will warrant reduction in its dose. These studies are geared towards bringing back EMT or its 
derivatives to the clinical limelight in cancer chemotherapy. The present report summarizes 
these more recent anti-tumor updates on EMT (Table 1). It is hoped that this report will fur-
ther spur research interests on EMT and its structural modifications towards potential applica-
tion in cancer chemotherapy. 
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Table 1: Recent studies on EMT in relation to anti-cancer effect 
Cancer cell line Studies Reference 
Prostate (LNCaP, 
PC3),  
breast (MCF7 and 
MDA-MB-231) and 
in normal human 
prostatic epithelial 
cell line (PrEC) 
EMT was derivatized at its N-2′ position such that it can be se-
lectively delivered as a prodrug to be activated by an enzyme, 
fibroblast activation protein (FAP) which is selectively overex-
pressed within the metastatic tumor to cancer cells. Eleven 
peptidyl EMT prodrug analogs were synthesized and tested for 
in-vitro activation by FAP. It was shown that one of the pro-
drugs, a dipeptidyl peptidase-4 (DPPIV) activatable derivative, 
is activated to EMT (70 % in 24 h) and cytotoxicity studies in-
dicated its equipotence to EMT in the presence of FAP and 
DPPIV. The prodrug was over 200-fold less cytotoxic than 
EMT in the normal cell, PrEC cell line. 
Akinboye et 
al., 2016 
Prostate cell lines 
(DU145, PC3 and 
LNCaP) 
Novel EMT dithiocarbamate analogs were synthesized and 
characterized for anti-tumorigenic activity and minimal toxicity 
to normal prostate cells. Their targeted apoptotic regulatory 
genes were also studied. Two key compounds were found to 
have significant anti-tumor potential in the PC3 cells. 
Bamji et al., 
2015 
Bladder cancer 
It was shown that low nanomolar concentrations of EMT com-
pletely inhibit expression of HIF1α and HIF2α, but not HIF1β. 
The decrease in HIFα expression was due to protein synthesis 
inhibition and also proteasomal degradation. It was suggested 
that cancer patients may benefit from treatment with a HIFα 
inhibitor, like EMT given the important role of HIF proteins and 
hypoxia signaling in promoting tumor growth and progression. 
Foreman et 
al., 2015 
Ovarian cancer 
Co-administration of cisplatin and EMT not only remarkably 
induced apoptosis but also reduced the colony formation of 
the tumor cells. The apoptosis was dependent on the activa-
tion of caspases -3, -7 and -8 and downregulation of bcl-xL by 
EMT.  
Sun et al., 
2015 
Lung cancer p38, 
ERK and JNK 
EMT inhibits migration and invasion of human non-small-cell 
lung cancer (NSCLC) cells. The drug differentially regulates 
two (p38 and ERK) out of the three major mitogen-activated 
protein kinases (MAPKs), p38, ERK and JNK which leads to 
the selective down-regulation of matrix metalloproteinases-2 
and -9 (MMP-2 and MMP-9), two major gelatinases which can 
degrade extracellular matrix components and allow cancer 
cells to spread out from its origin. 
Kim et al., 
2015 
Cancer stem cells 
A library search of leads having cancer stem cell (CSC) target-
ing ability as well as the capability of modulating multiple tar-
get proteins was done through in silico experiments which 
screened a number of alkaloids. The findings indicated that 
EMT and cortistatin have the ability to modulate hedgehog 
(Hh) pathway. The proposed mechanism is by binding to sonic 
hedgehog (Hh), smoothened (Smo) and Gli protein which are 
involved in maintenance of CSCs. 
Mayank and 
Jaitak, 2015 
AsPC-1 pancreatic 
cancer cell 
EMT was one of the compounds identified to sensitize the 
pancreatic tumor cells to tumor necrosis factor-related apopto-
sis-inducing ligand (TRAIL)-induced apoptosis. It was sug-
gested that myeloid cell leukemia sequence-1 (Mcl-1) is in-
volved in pancreatic cancer cell resistance to TRAIL and EMT 
facilitates the apoptosis of TRAIL-resistant pancreatic cancer 
cells by specifically inhibiting the protein function of Mcl-1. 
Han et al., 
2014 
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Cancer cell line Studies Reference 
Acute myeloid  
leukemia (AML) cells 
A liposomal formulation encapsulating both daunorubicin 
(DNR) and EMT was developed for enhanced cytotoxic effect 
against acute myeloid leukemia (AML) cells to overcome some 
of the problems of DNR chemotherapy. 
Myhren et al., 
2014 
Bladder cancer 
EMT and cisplatin individually and in combined inhibited blad-
der cancer cell proliferation synergistically primarily by arrest 
of tumor cell growth rather than by apoptosis. 
Foreman et 
al., 2013 
Prostate PC3 and 
LNCaP 
The N-2′ position of the EMT was derivatized to thiourea, urea, 
sulfonamide, dithiocarbamate, carbamate and pH responsive 
hydrolysable amide analogs which generally exhibited less cy-
totoxicity (IC50 ranging from 0.079 to 10 μM) than EMT (IC50 
ranging from 0.0237 to 0.0329 μM).  
Akinboye et 
al., 2012 
Human pancreatic 
(BON-1), and  
bronchial (NCI-H727 
and NCI-H720)  
cell lines 
A study was conducted to study the cytotoxic activity of EMT 
and CGP-74514A in a three-dimensional model and to study if 
the mechanism of the cytotoxic activity was induction of apop-
tosis. The cytotoxic activity was done using an in vitro hollow 
fiber model while a multiparametric high-content screening as-
say was used for measurement of apoptosis. The cancer cells 
tested were human pancreatic carcinoid cell line, BON-1, and 
the human typical and atypical bronchial carcinoid cell lines 
NCI-H727 and NCI-H720. Both drugs showed antitumor activi-
ty and induced caspase-3 activation indicating apoptosis. 
Larrson et al., 
2012 
Prostate PC3 cells; 
cervical C33A cells, 
breast cancer MCF-
7 cells and MCF-
7/Adr cells 
The regulation of the alternative splicing of caspase 9 pre-
mRNA was examined in response to EMT hydrochloride. It 
was suggested that the various splicing patterns of the caspa-
se 9 gene regulated by EMT and other agents may contribute 
to the resistance or sensitization of the tumors to other cell 
death inducers. 
Pan et al., 
2011 
786-O cell line,  
a von Hippel-Lindau 
(VHL)-deficient clear 
cell renal cell carci-
noma (CCRCC) cell  
EMT was identified as a specific inhibitor of hypoxia-inducible 
factor-2 (HIF-2), protein stability and transcriptional activity. 
The data from the study support the identification of novel HIF-
2 inhibitors through the use of EMT or structurally related 
compounds as lead compounds. 
Kong et al., 
2010 
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